96 Tests PN: B111425F
45x Ab-conjugated beads (S4P12 - Human IL-35 Ab-bead). PN: B111425A. One vial containing 100 µL of anti-human IL-35 (p35 subunit) conjugated to AimPlex Bead S4P12.
25x Biotin-detection Ab (Human IL-35 Biotin-dAb).PN: B111425B. One vial containing 100 µL of biotinylated anti-human IL-35 (EBI3 subunit).
Lyophilized Standard Mix - Human IL-23 and IL-35. PN: HIL 12F2B. One vial containing lyophilized recombinant human IL-23 and IL-35. Note: If multiple analyte kits on the above target list are ordered as a panel, only one vial of standard mix is supplied for those analyte kits.
Application: Optimal antibody pair and antigen standard for assaying human IL-35. Can be multiplexed with human IL-23. To be used in conjunction with the AimPlex NR Basic Kit (PN: P100001) and a diluent kit. Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure.
Storage: 2-8 C in the dark.
Important: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.
For Research Use Only. Not for use in diagnostic procedures.
Sample types: Cell culture supernatant, serum, plasma, bodily fluid and tissue/cell lysate
Sensitivity (LOD): < 5 pg/mL
LLOQ: < 10 pg/mL
ULOQ: > 5,000 pg/mL
Standard dose recovery: 70-130%
Intra-assay CV: < 10%
Inter-assay CV: < 20%
Cross-reactivity of analytes in Human Group 3: Negligible
Sample volume: 15 µL/test
Interleukin 35 (IL-35) is an IL-12 family cytokine produced by regulatory, but not effector, T-cells and plays a role in immune suppression. It is a dimeric protein composed of IL-12α and IL-27β chains and is secreted by regulatory T-cells (Tregs). IL-35 suppresses inflammatory responses of immune cells. IL-35 is not constitutively expressed in tissues, but the gene encoding IL-35 is transcribed by vascular endothelial cells, smooth muscle cells and monocytes after activation with proinflammatory stimuli. Studies in mice show the absence of either IL-35 chain from regulatory Tregs reduces the cells' ability to suppress inflammation; this has been observed during cell culture experiments and using an experimental model for inflammatory bowel diseaseTo produce its suppressive effects (eg on collagen-induced arthritis), IL-35 has selective activities on different T-cell subsets; it induces proliferation of Treg cell populations but reduces activity of Th17 cell populations.
Li X, Mai J, Virtue A, et al. (March 2012). "IL-35 is a novel responsive anti-inflammatory cytokine—a new system of categorizing anti-inflammatory cytokines". PLoS ONE 7 (3): e33628. doi:10.1371/journal.pone.0033628. PMID 22438968.
Collison LW, Workman CJ, Kuo TT, et al. (November 2007). "The inhibitory cytokine IL-35 contributes to regulatory T-cell function". Nature 450 (7169): 566–9. doi:10.1038/nature06306. PMID 18033300.
Niedbala W, Wei XQ, Cai B, et al. (November 2007). "IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells". Eur. J. Immunol. 37 (11): 3021–9. doi:10.1002/eji.200737810. PMID 17874423.